 |
PDBsum entry 3sek
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Signaling protein
|
PDB id
|
|
|
|
3sek
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Biol Chem
287:1043-1053
(2012)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.
|
|
J.N.Cash,
E.B.Angerman,
C.Kattamuri,
K.Nolan,
H.Zhao,
Y.Sidis,
H.T.Keutmann,
T.B.Thompson.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
TGF-β family ligands are involved in a variety of critical physiological
processes. For instance, the TGF-β ligand myostatin is a staunch negative
regulator of muscle growth and a therapeutic target for muscle-wasting
disorders. Therefore, it is important to understand the molecular mechanisms of
TGF-β family regulation. One form of regulation is through inhibition by
extracellular antagonists such as the follistatin (Fst)-type proteins. Myostatin
is tightly controlled by Fst-like 3 (Fstl3), which is the only Fst-type molecule
that has been identified in the serum bound to myostatin. Here, we present the
crystal structure of myostatin in complex with Fstl3. The structure reveals that
the N-terminal domain (ND) of Fstl3 interacts uniquely with myostatin as
compared with activin A, because it utilizes different surfaces on the ligand.
This results in conformational differences in the ND of Fstl3 that alter its
position in the type I receptor-binding site of the ligand. We also show that
single point mutations in the ND of Fstl3 are detrimental to ligand binding,
whereas corresponding mutations in Fst have little effect. Overall, we have
shown that the NDs of Fst-type molecules exhibit distinctive modes of ligand
binding, which may affect overall affinity of ligand·Fst-type protein complexes.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |
|